THE Therapeutic Goods Administration (TGA) has approved AstraZeneca's submission to change the name of its COVID-19 vaccine (COVAX) to Vaxzevria.
The name change brings the CSL-produced shot in line with the branding in the European Union and Canada.
The move is expected to alleviate confusion and facilitate international recognition for Australians who have received the AZ shot, when travel restrictions are eased.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Aug 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Aug 21
